Glofitamab Shows Benefit Regardless of Prior BTK Exposure in R/R MCL

Commentary
Video

All patient populations benefitted from glofitamab in a phase 1/2 trial, but the design excluded capture of high-risk features present in similar studies.

All patient subgroups with relapsed/refractory mantle cell lymphoma (MCL) appeared to benefit from treatment with glofitamab-gxbm (Columvi), even among groups with or without prior exposure to Bruton’s tyrosine kinase (BTK) inhibitors and those with COVID-19 related events, according to Tycel Phillips, MD.

Phillips, an associate professor in the Division of Lymphoma and Department of Hematology & Hematopoietic Stem Cell Transplantation at City of Hope in Duarte, California, spoke with CancerNetwork® during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting about an analysis from a phase 1/2 study (NCT03075696) evaluating glofitamab monotherapy in patients with heavily pretreated relapsed/refractory MCL.

He highlighted a lack of disparity in outcomes among patient populations who appeared to derive equal efficacy from glofitamab, especially in the post-BTK setting. However, he noted that the trial was not designed to focus on many high-risk disease features that investigators typically report in other MCL studies. According to Phillips, the agent may be usable among country-wide centers accustomed to the use of bispecific antibodies to increase the accessibility of T-cell therapies for MCL.

Transcript:

As of right now, we don’t really have a true subset analysis, but overall, we didn’t see a patient population that did not benefit from it. Unfortunately, as the trial was designed, we didn’t really capture a lot of those high-risk features that typically are present in a lot of these mantle cell lymphoma studies. Overall, [across] the BTK-exposed or BTK-naïve [groups], which are probably the big 2 categories we can separate patients into, we really didn’t see a difference in outcomes again, especially.If we do center some of the COVID-19 related events, it does appear that these patients receive equal efficacy. If you look at a post-BTK setting, this is a very effective drug. A drug that, again, as more centers get used to using bispecific antibodies, is something that can be given throughout the country, and will increase the accessibility of a T-cell directed therapy for all patients with mantle cell lymphoma.

Reference

Phillips TJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): updated analysis from a phase I/II study. J Clin Oncol. 2024;42(suppl 16). doi:10.1200/JCO.2024.42.16_suppl.700

Recent Videos
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Generally, the communication in academic oncology institutions is favorable; however, when oncologists and pathologists become busy, specimens may be sent to reference laboratories.
Hydration and a healthy, well-balanced diet may mitigate fatigue among patients undergoing treatment for cancer.
The medical characteristics of a patient may heavily factor into the selection of tyrosine kinase inhibition for the treatment of chronic myeloid leukemia.
Bland foods, such as crackers and chicken noodle soup, as well as fluids with electrolytes, may help stave off treatment-related nausea.
The toxicity profile of interferon and the limited availability of transplantation established a need for TKI development for chronic myeloid leukemia.
Predictors of response have a significant effect on clinical decision-making because they may help oncologists select the best treatment for specific patients.
Related Content